Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02929056 · ClinicalTrials.gov registry record · Phase 4
Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations
A Phase 4 study, sponsored by Prisma Health-Upstate.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT02929056 is a Phase 4 study that was terminated before completion, run by Prisma Health-Upstate. The registered enrollment target is 2 participants.
The verdict
NCT02929056, a Phase 4 study, was terminated before completion, sponsored by Prisma Health-Upstate.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate and compare healing characteristics, reduction in the size of the wound and to measure complete healing of the wound following the application of a biologic product dressing instead of the alginate dressing along with standard debridement and compression therapy versus the standard of care treatment for VLUs. The biologic product that will be used in this study is called AmnioExCel™.
Interventions
- BIOLOGICAL AmnioExCel dressing and compression therapy
- PROCEDURE SOC alginate dressing and compression therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2019-10-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02929056
The ClinicalTrials.gov registry entry for NCT02929056 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AmnioExCel dressing and compression therapy is the first listed.
NCT02929056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02929056 about?
NCT02929056 is a clinical study titled "Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations". The purpose of this study is to evaluate and compare healing characteristics, reduction in the size of the wound and to measure complete healing of the wound following the application of a biologic product dressing instead of the alginate dressing along with standard debridement and compression ther...
What is the current status of trial NCT02929056?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2017-02-15. Estimated completion is 2019-10-29.
What interventions are being tested in trial NCT02929056?
The interventions under investigation include: AmnioExCel dressing and compression therapy (BIOLOGICAL), SOC alginate dressing and compression therapy (PROCEDURE).
Who is sponsoring clinical trial NCT02929056?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.